Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPH-104 in Adult Onset Still's Disease
NCT05432960Phase 3Withdrawn
- Sponsor
- R-Pharm
- Start
- Dec 2023
- Primary completion
- Aug 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of goflikicept in adult-onset Still's disease (AOSD) (3 arms), sponsored by R-Pharm. Primary endpoint: Time to Exacerbation of AOSD at 24 weeks. Planned start Dec 2023; status: withdrawn.
02
Drugs
goflikicept
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NCT05432960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432960.